Prostate Cancer Trial, Recruiting NCT06171139 Sponsor: University of California, San Francisco Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06171139
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You identify as Black or African American (including mixed-race with Black or African American heritage) — this can be based on your own self-report
  • You have been told you have prostate cancer that has spread to other parts of the body (metastatic prostate cancer) — no formal pathology report is needed, your own report is acceptable
  • You are able to understand what the study involves and are willing to follow the study procedures for the full duration
  • You are fluent in English (reading, writing, and speaking)
  • (For one part of the study only) Your cancer doctor expects that tumor genetic testing — such as analyzing cancer DNA from tissue or a blood sample — will be discussed with you within the next year of joining the study (confirm with trial site)

Who may not be able to join:

  • You have a medical reason that would prevent you from safely taking part in any of the study's procedures or assessments (confirm with trial site for specifics)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Daniel Kwon, MD, University of California, San Francisco

Phone: 877-827-3222

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 December 2023
Est. completion
31 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Frequency of participant responses (Stage 1); Proportion of enrolled participants (Stage 2); Proportion of enrolled participants who review all educational materials (Stage 2); Mean score of Feasibility of Intervention Measure (FIM) (Stage 2)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov